TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39085322

Group type: EXPERIMENTAL
Intervention: Topical solution of plant terpenes containing camphor, menthol, eugenol, eucalyptol, and vanillin with 15% DMSO, 1% limonene, and rosemary oil applied topically twice daily.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study: 39085438

Group type: EXPERIMENTAL
Intervention: Breastfeeding training with virtual reality (VR) at 4th and 24th hours after cesarean delivery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard breastfeeding training
Number of subjects: 66
Study: 39085487

Group type: EXPERIMENTAL
Intervention: selpercatinib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: wearable technology
Number of subjects: 1
Study: 39085664

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (AUR)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combination of Auriculotherapy and Acupuncture (AUR-ACU)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual Treatment (UT)
Number of subjects: 115
Study: 39085698

Group type: EXPERIMENTAL
Intervention: Osteoporosis Awareness Scale (OAS)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Revised Osteoporosis Knowledge Test (R-OKT)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Fall risk assessment using timed up-and-go test
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Correlation between OAS scores and fall risk
Number of subjects: 325
Study: 39085782

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 160
Study: 39085831

Group type: EXPERIMENTAL
Intervention: SMP (6 weekly sessions)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SMP + HBCC (6 weekly sessions)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 34
Study: 39085889

Group type: EXPERIMENTAL
Intervention: Family history of cancer (FHC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Family history of lung cancer
Number of subjects: 53

Group type: COMPARATOR
Intervention: Germline mutations (ATM, BRCA2, TP53)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FAHIC-Lung study
Number of subjects: 53
Study: 39085927

Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle interventions (MLI) - 3 months of weekly 2-hour sessions on diet education, yoga, music therapy, and cognitive skills training.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle interventions (MLI)
Number of subjects: 200
Study: 39085940

Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies employed by first-line managers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Barriers to guideline implementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Organizational support for CPG implementation
Number of subjects: 30
Study: 39085951

Group type: EXPERIMENTAL
Intervention: TENS with active TaVNS (25 Hz, 200 µs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TENS with placebo TaVNS
Number of subjects: 30
Study: 39085979

Group type: EXPERIMENTAL
Intervention: Strict BP control (SBP < 130 mmHg)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Standard BP control (SBP < 140 mmHg)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Achieved average SBP of 130-139 mmHg
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Achieved average SBP < 130 mmHg
Number of subjects: 341
Study: 39086130

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 622
Study: 39086144

Group type: EXPERIMENTAL
Intervention: Individual Packer Managing Fatigue program
Number of subjects: 0
Study: 39086163

Group type: EXPERIMENTAL
Intervention: Circadian Rhythm for Mood (CRM) digital therapeutic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 39086310

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 192
Study: 39086673

Group type: EXPERIMENTAL
Intervention: rAAV-mediated gene augmentation therapy for GSD-Ia (NCT05139316)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA augmentation for GSD-Ia (NCT05095727)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative genetic technologies for GSD-I therapies (gene editing)
Number of subjects: 0
Study: 39086728

Group type: EXPERIMENTAL
Intervention: Active deep H-coil rTMS targeting the primary motor cortex
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham deep H-coil rTMS targeting the primary motor cortex
Number of subjects: 17
Study: 39086857

Group type: EXPERIMENTAL
Intervention: Functional fitness training and mastering physical literacy class twice a week with buddy peer support for 12 weeks, including reflective writing journal.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 10
Study: 39086948

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study: 39086991

Group type: EXPERIMENTAL
Intervention: FODMAP-lowering diet supported by a smartphone application for 8 weeks
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: FODMAP-lowering diet supported by a smartphone application
Number of subjects: 222
Study: 39087204

Group type: EXPERIMENTAL
Intervention: Foster families
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nursing homes
Number of subjects: 107
Study: 39087355

Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no valsartan treatment)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subclinical HCM
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early stage HCM
Number of subjects: 200
Study: 39087564

Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 659
Study: 39087734

Group type: EXPERIMENTAL
Intervention: Concurrent trauma-focused and personality disorder treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Only trauma-focused treatment
Number of subjects: 0
Study: 39087741

Group type: EXPERIMENTAL
Intervention: Perclose ProGlide (PPG) Suture-Mediated Closure System
Number of subjects: 100

Group type: COMPARATOR
Intervention: figure of 8 suture
Number of subjects: 100
Study: 39087785

Group type: EXPERIMENTAL
Intervention: sRBC transfusion
Number of subjects: 174

Group type: COMPARATOR
Intervention: Baseline samples
Number of subjects: 174

Group type: COMPARATOR
Intervention: pRBCs
Number of subjects: 174
Study: 39087868

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 mg three times daily before meals (BM-TID)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 mg three times daily after meals (AM-TID)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg four times daily after meals (AM-QID)
Number of subjects: 327
Study: 39088062

Group type: EXPERIMENTAL
Intervention: Pre-hospital heparin administration
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group (no pre-hospital heparin)
Number of subjects: 394
Study: 39088076

Group type: EXPERIMENTAL
Intervention: Prolonged awake prone positioning (target > 12 h daily for 7 days)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Standard care (shorter period of awake prone positioning)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Prolonged awake prone positioning
Number of subjects: 409

Group type: COMPARATOR
Intervention: Prolonged awake prone positioning and Standard care
Number of subjects: 409
Study: 39088196

Group type: EXPERIMENTAL
Intervention: Lobar resection
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 697

Group type: COMPARATOR
Intervention: Patients with pT1 tumors
Number of subjects: 697

Group type: COMPARATOR
Intervention: Patients with pT2 tumors
Number of subjects: 697
Study: 39088200

Group type: EXPERIMENTAL
Intervention: AI-enabled ultrasonography tool (index test)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard biometry by credentialed sonographers (study standard)
Number of subjects: 400
Study: 39088212

Group type: EXPERIMENTAL
Intervention: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA) among APOE*E4 carriers
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (soybean oil)
Number of subjects: 102
Study: 39088215

Group type: EXPERIMENTAL
Intervention: EHR-based multifactorial intervention screening (noninterruptive EHR alert combined with confidential screening by computer questionnaire)
Number of subjects: 8895

Group type: EXPERIMENTAL
Intervention: Confidential screening process
Number of subjects: 8895
Study: 39088218

Group type: EXPERIMENTAL
Intervention: Investigational 4-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control 4-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 208
Study: 39088254

Group type: EXPERIMENTAL
Intervention: OKquit smartphone app for smoking cessation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard OTH care (SC)
Number of subjects: 500
Study: 39088271

Group type: EXPERIMENTAL
Intervention: CE+p55Gag
Number of subjects: 56

Group type: COMPARATOR
Intervention: p55Gag
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 56
Study: 39088339

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 130
Study: 39088370

Group type: EXPERIMENTAL
Intervention: Binaural beats intervention, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 39088398

Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen deprivation therapy (ADT); 240 mg daily for 12 cycles (28-day cycles)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT; 12 months after treatment completion
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 108
Study: 39088460

Group type: EXPERIMENTAL
Intervention: Self-report distress tool (DT)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rapid mental health referral process (MH)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual case management (C)
Number of subjects: 400
Study: 39088470

Group type: EXPERIMENTAL
Intervention: Active Choice (AC) intervention
Number of subjects: 743

Group type: COMPARATOR
Intervention: Passive Choice (PC) control group
Number of subjects: 743
Study: 39088510

Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Motivational counselling on physical activity (PA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Higher number of daily steps
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Active kilocalories during pregnancy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 150
Study: 39088766

Group type: EXPERIMENTAL
Intervention: Nurse-led two-session intervention (focused on breathing techniques, postural positions, and fan therapy)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 247
Study: 39088774

Group type: EXPERIMENTAL
Intervention: Devimistat (CPI-613) plus modified FFX (mFFX)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Standard-dose FFX
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Devimistat plus mFFX
Number of subjects: 528
Study: 39089004

Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg once daily (cohort A)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Befotertinib 75-100 mg once daily (cohort B)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg once daily (cohort A) with brain metastasis
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg once daily (cohort A) without brain metastasis
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Befotertinib 75-100 mg once daily (cohort B) with brain metastasis
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Befotertinib 75-100 mg once daily (cohort B) without brain metastasis
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Befotertinib (both cohorts)
Number of subjects: 466
Study: 39089011

Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporary conventional cardiopulmonary bypass (cCPB)
Number of subjects: 0
Study: 39089109

Group type: EXPERIMENTAL
Intervention: Digital biomarkers based on sensor data from a wrist-worn wearable, including heart rate variability and skin conductance levels, combined with deep-learning features from a self-supervised convolutional autoencoder.
Number of subjects: 0
Study: 39089293

Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 39089299

Group type: EXPERIMENTAL
Intervention: Quantitative PPP nomogram
Number of subjects: 2414

Group type: EXPERIMENTAL
Intervention: Visual PPP nomogram
Number of subjects: 2414
Study: 39089305

Group type: EXPERIMENTAL
Intervention: Tepotinib plus osimertinib (oral tepotinib 500 mg plus oral osimertinib 80 mg once daily)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Tepotinib plus osimertinib
Number of subjects: 128
Study: 39089326

Group type: EXPERIMENTAL
Intervention: Positive imagery instructions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neutral imagery instructions
Number of subjects: 26
Study: 39089519

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg once-daily
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 39089517

Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) of LNPCPs
Number of subjects: 2956

Group type: COMPARATOR
Intervention: Direct surgery for LNPCPs
Number of subjects: 2956
Study: 39089633

Group type: EXPERIMENTAL
Intervention: STRIDE
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: durvalumab
Number of subjects: 479

Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 479
Study: 39089652

Group type: EXPERIMENTAL
Intervention: Probiotic preparation containing Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175 over 60 days
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 39089718

Group type: EXPERIMENTAL
Intervention: Access to protein signature with top-down treatment algorithm (anti-tumour necrosis factor agent with/without an immunomodulator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical management based on stepwise escalation of treatment after failure of first-line treatment
Number of subjects: 0
Study: 39089896

Group type: EXPERIMENTAL
Intervention: Therapeutic education (intensive follow-up schedule of phone calls, home visits, text messages, plus cardiologist visits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (standard appointments with cardiologist and general practitioner)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 39089900

Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Number of subjects: 126

Group type: COMPARATOR
Intervention: Virtual Reality
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study: 39090192

Group type: EXPERIMENTAL
Intervention: ADE-RS5 (5-gene-drug resistance score)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: pLSC6 (leukemic-stemness signature)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Group-4 (high-scores for ADE-RS5 and pLSC6)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Group-2/3 (one high and one low-score)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Group 2 vs. Group 1
Number of subjects: 163

Group type: COMPARATOR
Intervention: Group 3 vs. Group 1
Number of subjects: 163

Group type: COMPARATOR
Intervention: Group 4 vs. Group 1
Number of subjects: 163
Study: 39090218

Group type: EXPERIMENTAL
Intervention: Online-delivered resistance exercise intervention (n=28)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Minimal contact control (MCC) (n=24)
Number of subjects: 52
Study: 39090323

Group type: EXPERIMENTAL
Intervention: N-L-NMMA at 250 μg/kg per minute combined with trimethaphan at 4 mg/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (White women)
Number of subjects: 10
Study: 39090517

Group type: EXPERIMENTAL
Intervention: PFMT combined with Otago exercises
Number of subjects: 43

Group type: COMPARATOR
Intervention: PFMT alone
Number of subjects: 43
Study: 39090589

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) visits
Number of subjects: 11030

Group type: COMPARATOR
Intervention: Health facility/pharmacy visits
Number of subjects: 11030

Group type: EXPERIMENTAL
Intervention: Reported malaria treatment
Number of subjects: 11030

Group type: EXPERIMENTAL
Intervention: Reported malaria treatment among febrile individuals
Number of subjects: 11030

Group type: EXPERIMENTAL
Intervention: Factors associated with healthcare seeking
Number of subjects: 11030
Study: 39090600

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) plus bile duct stenting
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bile duct stenting alone
Number of subjects: 120
Study: 39090664

Group type: EXPERIMENTAL
Intervention: Cognitive-motor intervention based on immersive virtual reality (VR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional cognitive training
Number of subjects: 34
Study: 39090770

Group type: EXPERIMENTAL
Intervention: Magnetic single-anastomosis side-to-side duodeno-ileostomy (MagDI) using the novel linear magnetic anastomosis system (LMAS [3 cm])
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Magnetic single-anastomosis side-to-side duodeno-ileostomy (MagDI)
Number of subjects: 24
Study: 39091032

Group type: EXPERIMENTAL
Intervention: Third-person self-talk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39091122

Group type: EXPERIMENTAL
Intervention: Targeted health dialogues (THDs)
Number of subjects: 1831
Study: 39091324

Group type: EXPERIMENTAL
Intervention: efmoroctocog alfa prophylaxis
Number of subjects: 189
Study: 39091353

Group type: EXPERIMENTAL
Intervention: Mild anemia
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Moderate or severe anemia
Number of subjects: 1071

Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Anemia (overall)
Number of subjects: 1071
Study: 39091509

Group type: EXPERIMENTAL
Intervention: CDS tool with behavioral nudges
Number of subjects: 1527

Group type: COMPARATOR
Intervention: CDS tool without behavioral nudges (control)
Number of subjects: 1527
Study: 39091606

Group type: EXPERIMENTAL
Intervention: Gumarontinib
Number of subjects: 32
Study: 39091640

Group type: EXPERIMENTAL
Intervention: Increased levels of interleukin 9
Number of subjects: 452

Group type: COMPARATOR
Intervention: Disease-free controls
Number of subjects: 452
Study: 39091670

Group type: EXPERIMENTAL
Intervention: Deoxycytidine/deoxythymidine (dC/dT) combination therapy
Number of subjects: 10
Study: 39091669

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (Allisartan starting at 80 mg/day, increased to 160 mg/day at month 2, combined with amlodipine 2.5 mg/day at month 4 if BP remained uncontrolled)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 39091672

Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (Part A)
Number of subjects: 39
Study: 39091673

Group type: EXPERIMENTAL
Intervention: 2-dose mRNA-1273 100 μg
Number of subjects: 2490

Group type: EXPERIMENTAL
Intervention: Single dose of mRNA-1273 50 μg
Number of subjects: 2490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2490
Study: 39091678

Group type: EXPERIMENTAL
Intervention: Elevase® enzyme blend
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39092032

Group type: EXPERIMENTAL
Intervention: Standard fasting (Group-A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Liberal fasting (Group-B)
Number of subjects: 120
Study: 39093227

Group type: EXPERIMENTAL
Intervention: cGMP-manufactured WJMSCs
Number of subjects: 0
Study: 39093262

Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg sodium (284 mg inclisiran)
Number of subjects: 2975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2975
Study: 39093380

Group type: EXPERIMENTAL
Intervention: NSPIT plus 500 mg of oral systemic metronidazole three times a day for 7 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: NSPIT plus placebo
Number of subjects: 21
Study: 39093385

Group type: EXPERIMENTAL
Intervention: Latero-lateral duodeno-ileostomy + Sleeve Gastrectomy with Magnet Anastomosis System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard SADI-S
Number of subjects: 0
Study: 39093566

Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention (12-minute video with 4 Spanish-language stories)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Printed, culturally tailored T2D education materials (control group)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention
Number of subjects: 451
Study: 39093639

Group type: EXPERIMENTAL
Intervention: Telemedicine support
Number of subjects: 1393

Group type: COMPARATOR
Intervention: Usual PICU care
Number of subjects: 1393
Study: 39093661

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at weeks 0 and 4, then every 12 weeks through week 52
Number of subjects: 55
Study: 39093662

Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Vegan Capsules, Nutraceutical Wellness, Inc.
Number of subjects: 95
Study: 39093916

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 50
Study: 39093981

Group type: EXPERIMENTAL
Intervention: Triplet regimen of chidamide, decitabine, and anti-PD-1 camrelizumab (CDP)
Number of subjects: 52
Study: 39094065

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39094377

Group type: EXPERIMENTAL
Intervention: Custom-made insoles adapted to flip-flops
Number of subjects: 80